Premium valuation, soft growth
The P/E of 47.57× is above the personal care median (35.16×) while profit grew 0.5% last year.
Importance 62 / 95 · valuation
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
The P/E of 47.57× is above the personal care median (35.16×) while profit grew 0.5% last year.
Importance 62 / 95 · valuation
Profit has swung sharply over 4 years (from ₹-561 to ₹1,861) — one year is a weak guide to the earnings power.
Importance 57 / 95 · growth
Free cash flow has been positive in 5 of the last 5 years.
Importance 44 / 95 · cash quality
Classified by the exchange under Fast Moving Consumer Goods › Fast Moving Consumer Goods › Personal Products › Personal Care.
Peer set used on this page: 3 personal care.
Revenue grew 5.4% a year over 4 years, from ₹12,277 cr in FY2022 to ₹15,178 cr in FY2026. Net profit grew 1.1% a year over the same period.
Profit has swung sharply over 4 years (from ₹-561 to ₹1,861) — one year is a weak guide to the earnings power.
Rule EARNINGS_VOLATILE
Revenue has compounded at 5.4% a year over 4 years (₹12,277 → ₹15,178) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,413 cr (up 15.4% on the same quarter last year) and net profit ₹523 cr (up 13.8%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 revenue was ₹4,413 cr, up 15.4% from ₹3,825 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 net profit was ₹523 cr, up 13.8% from ₹459 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 revenue of ₹4,413 cr is the highest of the 14 quarters on record for this company.
Rule QTR_REVENUE_AT_RECORD
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 3,768 | +3.0% | 498 | −14.2% | 13.2% |
| Q4 FY25 | 3,598 | +6.3% | 412 | −121.8% | 11.4% |
| Q1 FY26 | 3,662 | +9.9% | 452 | +0.4% | 12.4% |
| Q2 FY26 | 3,825 | +4.3% | 459 | −6.5% | 12.0% |
| Q3 FY26 | 4,099 | +8.8% | 498 | −0.1% | 12.1% |
| Q4 FY26 | 3,900 | +8.4% | 452 | +9.7% | 11.6% |
| Q1 FY27 | 4,225 | +15.4% | 505 | +11.5% | 11.9% |
| Q2 FY27 | 4,413 | +15.4% | 523 | +13.8% | 11.8% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 22.5% in FY2026, against 20.2% in FY2022. ROE was 15.1% and ROCE 19.3% in FY2026.
Margin and return trends are shown above.
Debt-to-equity was 0.33x in FY2026, against 0.14x in FY2022; interest coverage 9.51x. Operating cash flow was 1.34x net profit.
Free cash flow has been positive in 5 of the last 5 years.
Rule FCF_CONSISTENTLY_POSITIVE
Within its 3-company Personal Care peer group, it ranks 3 of 3 on return on equity and 3 of 3 on EBITDA margin. Its P/E of 47.6 compares with a peer median of 35.2.
Ranked against 3 personal care (FY2026, consolidated).
GODREJCP · 1st of 3 · set median 5.0%
GODREJCP · 3rd of 3 · set median 23.1%
GODREJCP · 3rd of 3 · set median 16.2%
GODREJCP · 3rd of 3 · set median 35.2×
The P/E of 47.57× is above the personal care median (35.16×) while profit grew 0.5% last year.
Rule PRICED_FOR_GROWTH
On the trailing twelve months. Last full year: P/E 50.5× · P/S 6.1× · ROE 15.1%.
The share price is down 18.5% over 1 year, down 8.1% over 3 years (−2.8% a year) and flat over 5 years (flat a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 26.7% below its 52-week high.
Long-term price performance is shown above.
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 12,277 | 13,316 | 14,096 | 14,364 | 15,178 |
| Total income | 12,366 | 13,484 | 14,365 | 14,680 | 15,444 |
| EBITDA | 2,485 | 2,599 | 3,212 | 3,319 | 3,422 |
| Profit before tax | 2,155 | 2,133 | 198 | 2,672 | 2,590 |
| Net profit | 1,783 | 1,702 | −561 | 1,852 | 1,861 |
| EPS (₹) | 17.4 | 16.6 | −5.5 | 18.1 | 18.2 |
| Net worth | 11,556 | 13,794 | 12,599 | 12,004 | 12,653 |
| Total debt | 1,608 | 1,034 | 3,155 | 3,883 | 4,136 |
| Operating cash flow | 1,451 | 2,151 | 2,070 | 2,577 | 2,488 |
| Free cash flow | 1,174 | 1,931 | 1,793 | 2,018 | 1,946 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 8.5 | 5.9 | 1.9 | 5.7 |
| Profit growth YoY | — | -4.5 | -132.9 | — | 0.5 |
| Profitability | |||||
| EBITDA margin % | 20.2 | 19.5 | 22.8 | 23.1 | 22.5 |
| Net margin % | 14.4 | 12.6 | -3.9 | 12.6 | 12.1 |
| Return on equity % | 15.4 | 13.4 | -4.2 | 15.1 | 15.1 |
| Return on capital % | 17.3 | 16.9 | 19.4 | 19.5 | 19.3 |
| Leverage & cash | |||||
| Debt to equity | 0.14 | 0.07 | 0.25 | 0.32 | 0.33 |
| Cash flow ÷ profit | 0.81 | 1.26 | — | 1.39 | 1.34 |
| Current ratio | 1.43 | 1.76 | 0.99 | 1.06 | 0.91 |